The mifepristone lawsuit is the ongoing federal court fight over how the FDA regulates the country’s most widely used abortion medication. The Supreme Court unanimously rejected the original challenge in June 2024, ruling that the anti-abortion doctors who filed it had no legal standing. The case did not end there. The attorneys general of Missouri, Kansas, and Idaho had already intervened in the district court and refiled as the sole remaining plaintiffs, and in October 2025 the case was transferred to the Eastern District of Missouri, where it is actively contested in 2026. While the litigation continues, current FDA rules remain in force: mifepristone is approved through ten weeks of pregnancy, can be prescribed via telehealth, and can be dispensed by mail through certified pharmacies.
What the Supreme Court Decided
On June 13, 2024, the Supreme Court ruled 9–0 in FDA v. Alliance for Hippocratic Medicine that the plaintiffs could not bring the case. Justice Kavanaugh, writing for the Court, explained that Article III requires a plaintiff to show a concrete, personal injury caused by the defendant’s conduct.1Congress.gov. ArtIII.S2.C1.6.1 Overview of Standing The doctors and medical organizations behind the suit did not prescribe mifepristone and had not been forced to participate in any abortion-related care. Their objections were moral and ideological.
The Court noted that federal conscience-protection laws already shield medical professionals from being compelled to perform procedures they find morally objectionable, and the plaintiffs could not point to a single instance since 2000 in which a doctor was forced to provide abortion care despite a conscience objection.2U.S. Supreme Court. FDA v. Alliance for Hippocratic Medicine Because the case was decided entirely on standing, the Court never reached the underlying question of whether the FDA acted properly when it loosened the drug’s rules in 2016 and 2021.
Before that decision, the litigation had traveled a dramatic path. Judge Matthew Kacsmaryk in the Northern District of Texas issued a ruling in April 2023 that would have pulled mifepristone off the market entirely by enjoining the FDA’s original 2000 approval. The Fifth Circuit narrowed the order but still would have rolled the drug back to its 2000 conditions: a seven-week gestational limit, three in-person doctor visits, and no mail dispensing. The Supreme Court stayed those orders while it heard the case, so those restrictions never took effect.
Why the Case Isn’t Over
The three state attorneys general who intervened at the district court level were not affected by the standing ruling against the doctors. They stepped in as the remaining plaintiffs and kept the case alive. In October 2025 the case was transferred out of the Northern District of Texas to the Eastern District of Missouri.3Congressional Research Service. Medication Abortion: New Litigation May Affect Access Missouri, Kansas, and Idaho filed a supplemental complaint in December 2025. The FDA and the drug manufacturers Danco and GenBioPro filed motions to dismiss in March 2026, and the court has not yet ruled on those motions.
The states’ legal theory is different from the one the Supreme Court rejected. Rather than relying on doctors’ conscience concerns, they argue that easier access to mifepristone directly harms state interests. They claim it depresses birth rates, which they say reduces future state tax revenue, shrinks the population count used for congressional apportionment, and imposes costs on state hospitals when patients arrive in emergency rooms with complications that Medicaid does not fully cover. Whether any of that qualifies as a judicially recognizable injury is the central standing question the district court now has to work through.
What the Lawsuit Is Trying to Change
The target is two rounds of FDA rule changes. In 2016 the agency extended the approved use window from seven weeks to ten weeks and reduced required in-person visits from three to one.4Food and Drug Administration. Questions and Answers on Mifepristone for Medical Termination of Pregnancy Through Ten Weeks Gestation In 2021, it permanently dropped the requirement that patients pick up the drug in person, opening the door to telehealth prescriptions and pharmacy mail delivery. The plaintiffs also challenge the FDA’s decision to let certified non-physician providers prescribe the drug. If the states win on the merits, mifepristone access could be pushed back toward the pre-2016 framework.
What the FDA Rules Allow Right Now
The regulatory framework under attack remains fully in effect. Under the current Risk Evaluation and Mitigation Strategy, mifepristone can be used to terminate a pregnancy through ten weeks of gestation. A certified prescriber evaluates the patient, and that evaluation can happen through a telehealth consultation rather than an in-person visit. Once prescribed, the medication can be dispensed by a certified pharmacy by mail or picked up in person.5Food and Drug Administration. Information about Mifepristone for Medical Termination of Pregnancy Through Ten Weeks Gestation
Certified pharmacies must ship the medication using a tracked delivery service and provide the patient with an FDA-approved Medication Guide. Prescribers must complete a certification form confirming they can assess gestational age, diagnose ectopic pregnancies, and provide or arrange surgical intervention if needed.4Food and Drug Administration. Questions and Answers on Mifepristone for Medical Termination of Pregnancy Through Ten Weeks Gestation Out-of-pocket cost through telehealth providers generally runs from under $580 to around $800, depending on the provider and location.
Roughly 5.9 million women used mifepristone between 2000 and the end of 2022. FDA post-marketing data reports 32 deaths in that group, counted regardless of cause. Many involved factors unrelated to the medication, including homicides, overdoses, and pre-existing conditions.6Food and Drug Administration. Mifepristone US Post-Marketing Adverse Events
The Comstock Act Question
An older law hangs over the whole fight. The Comstock Act, codified at 18 U.S.C. §§ 1461–1462, prohibits mailing any “article or thing designed, adapted, or intended for producing abortion.”7U.S. Department of Justice. Application of the Comstock Act to the Mailing of Prescription Drugs That Can Be Used for Abortions Read broadly, that language could make it a federal crime to mail mifepristone anywhere.
The Biden administration’s Department of Justice issued a formal opinion concluding that the statute does not prohibit mailing mifepristone when the sender does not intend for the recipient to use it unlawfully. Under that reading, pharmacies shipping the drug to patients in states where medication abortion is legal are not violating the law. The state plaintiffs disagree and argue the FDA’s mail-dispensing rules conflict with the Comstock Act’s plain text. How the executive branch interprets and enforces the statute could reshape access without any court ruling in the pending case.
State Bans Are a Separate Track
Federal approval does not guarantee access everywhere, and the outcome of this lawsuit will not change that. As of early 2026, approximately 28 states restrict medication abortion in some form, and roughly 13 of those have total abortion bans covering both medication and procedural abortion. Some states that allow medication abortion impose extra requirements such as mandatory counseling, ultrasounds, or physician-only prescribing.
This patchwork exists because the FDA regulates drug safety and labeling at the federal level while states retain broad authority to regulate medical practice within their borders. Legal scholars have generally concluded that a state ban on mifepristone is not preempted by current federal drug law. The FDA’s approval means the drug meets federal safety standards and can be legally marketed; it does not prevent a state from prohibiting its use. So even a total FDA victory in the ongoing lawsuit would leave state-level bans intact, and even a plaintiff victory would not affect states that already prohibit the drug outright.